Clin2
NCT07714213Possibly a fitNot yet recruiting

Aripiprazole for post-infectious syndrome symptoms

Post-acute Infectious Syndrome (PAIS)Post-COVID-19 Condition (PCC or Long COVID)

Treatments studied

Part of Blood & lymphatic, Genetic & congenital, Infections, Lungs & breathing, Mental health clinical trials.

This trial tests if aripiprazole, a medication often used for other conditions, can help improve neuropsychiatric symptoms like brain fog, mood changes, or fatigue that started after an infection and have lasted at least 3 months.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
138 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • 18 years or older
  • Had a confirmed or suspected infection (like COVID-19, flu, or others) that may have triggered your symptoms
  • Have had ongoing symptoms for at least 3 months, including mental or emotional difficulties (like trouble concentrating, anxiety, or depression)
  • You are not currently taking antipsychotic medication
  • If you are a woman who can become pregnant, you must use highly effective birth control or be post-menopausal

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07724834Not yet recruiting· Phase 2
B-cell depletion for ME/CFS after infection

This trial tests whether a drug that targets B cells (a type of immune cell) can help people with ME/CFS and PAIS who have previously improved with a blood-filtering treatment called immunoadsorption. The goal is to see if this treatment can reduce symptoms and improve function.

Berlin
NCT05926505Recruiting· Phase 2/Phase 3
Anakinra for lingering symptoms after COVID-19

This Phase 2/3 trial studies whether anakinra can improve ongoing (post-acute) COVID-19 symptoms lasting for more than two months. It mainly looks for better safety and symptom improvement in people with specific inflammation and lung-related findings.

Jena
NCT07388550Not yet recruiting· Phase 1
Testing pembrolizumab for long COVID brain symptoms

This study tests whether a drug called pembrolizumab (a type of immunotherapy) can help people with ongoing neurological symptoms after COVID-19. The goal is to see if it is safe and possibly improves symptoms like brain fog, fatigue, and dizziness.

Bethesda, Maryland
NCT06928272Recruiting· Phase 3
Long COVID drug study for adults 18 to 65

This study tests whether a commonly used drug (repurposed) can help improve Long COVID symptoms like fatigue, breathing problems, or brain fog. It is for adults 18 to 65 who had COVID-19 in the past 4 years and still have symptoms after 3 months.

San Diego, California
NCT07076862Recruiting· Early Phase 1
PET scan study for long COVID symptoms

This study uses a special PET scan to look at inflammation in the body of people with long COVID (symptoms lasting 3+ months after infection). The goal is to understand why symptoms persist and find better ways to help.

Sacramento, California
NCT05656105Recruiting· Early Phase 1
PET scan study of brain inflammation after COVID

This early-phase study uses a special PET scan to look for signs of brain inflammation in people with ongoing (long-term) nervous system symptoms after COVID-19. It may help researchers understand what is driving symptoms and whether this imaging approach can detect inflammation.

Birmingham, Alabama

Hear when a new Post-acute Infectious Syndrome (PAIS) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.